Publications & News

WilmerHale Represents Curis in $45M Debt Transaction with HealthCare Royalty Partners

March 30, 2017

Curis, Inc., a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, announced a $45 million debt transaction with HealthCare Royalty Partners. The deal is meant to help fund an oncology pipeline for Curis.

The WilmerHale deal team that represented Curis included John Sigel and Eric French.

For more information read Curis' Fourth Quarter and Year-End Financial Results press release.